---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-055929"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:45:13.848089+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS reports Q3 net loss $0.6M; BREXAFEMME net sales $0.5M in first partial quarter

## Summary
- BREXAFEMME net sales $0.5M in partial Q3; IQVIA 1,006 prescriptions in Q3, 1,100 in October.
- R&D expense $4.4M (-45% YoY); SG&A $15.4M (+341% YoY driven by commercial launch costs).
- Net loss $0.6M ($0.02 per basic share) vs net income $0.9M in Q3 2020.
- Cash $100.1M; runway projected into 2023.
- CFO Eric Francois resigning; Danforth Advisors providing interim CFO Lawrence Hoffman.

## SEC filing metadata
- accession: 0001564590-21-055929
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000156459021055929/0001564590-21-055929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000156459021055929/scyx-8k_20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-055929
- JSON: https://secwatch.observer/filing/0001564590-21-055929.json
- Plain text: https://secwatch.observer/filing/0001564590-21-055929.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.